Search results
Results from the WOW.Com Content Network
CA-125 was initially detected using the murine monoclonal antibody designated OC125. Robert Bast , Robert Knapp and their research team first isolated this monoclonal antibody in 1981. [ 28 ] The protein was named "cancer antigen 125" because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied.
The condition is more common in older adults. [5] CPPD is estimated to affect 4% to 7% of the adult populations of Europe and the United States. [16] Previous studies have overestimated the prevalence by simply estimating the prevalence of chondrocalcinosis, which is found in many other conditions as well. [16]
1 patient out of 12 (8%) survived 10 years. All died within 6 months to 13.3 years. CDT between 6 months and 2 years: 11 patients out of 12 (92%) survived 5 years. 3 patients out of 8 (37%) survived 10 years. 4 patients out of 12 (25%) survived to the end of the study. CDT more than 2 years: 41 patients out of 41 (100%) were alive at the end of ...
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Body sites in which brachytherapy can be used to treat cancer. Brachytherapy is commonly used to treat cancers of the cervix, prostate, breast, and skin. [1]Brachytherapy can also be used in the treatment of tumours of the brain, eye, head and neck region (lip, floor of mouth, tongue, nasopharynx and oropharynx), [10] respiratory tract (trachea and bronchi), digestive tract (oesophagus, gall ...
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Iodine-125 (125 I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.